News Releases | BioAtla, Inc

Date
3/16/23	BioAtla to Announce Fourth Quarter and Full-Year 2022 Financial Results and Provide Business Highlights
2/27/23	BioAtla Announces Change in Executive Leadership
2/23/23	BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3182, a CAB-EpCAMxCAB-CD3 Bispecific T-Cell Engager for the Treatment of Advanced Adenocarcinoma
1/10/23	BioAtla Provides Clinical Program Updates and Upcoming 2023 Milestones